Regenxbio
RGNX
179 hedge funds and large institutions have $1.08B invested in Regenxbio in 2020 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 72 increasing their positions, 51 reducing their positions, and 16 closing their positions.
63% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 16
41% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 51
15% more capital invested
Capital invested by funds: $939M → $1.08B (+$144M)
14% more call options, than puts
Call options by funds: $5.76M | Put options by funds: $5.07M
5% more funds holding
Funds holding: 170 → 179 (+9)
0.89% more ownership
Funds ownership: 78% → 78.89% (+0.89%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$19.1M |
| 2 |
JP Morgan Chase
New York
|
+$15.4M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$10.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$10.4M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$17.1M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$12.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.2M |
| 4 |
O
OrbiMed
New York
|
-$8.67M |
| 5 |
WM
WS Management
Jacksonville,
Florida
|
-$7.42M |
RGNX Hedge Fund Activity: Q2 2020 in Review
179 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q2 2020, worth a combined $1.08B — up 15% from $939M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RGNX positions and 16 closed out — a net gain of 10 holders — while 72 added to existing stakes and 51 trimmed.
The largest buyer was BlackRock, adding an estimated $19.1M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $17.1M sold.
- 179 institutional investors held Regenxbio (RGNX) as of Q2 2020, up from 170 in Q1 2020.
- Funds reported $1.08B of Regenxbio stock for Q2 2020, up 15% quarter-over-quarter.
- 26 funds opened new Regenxbio positions in Q2 2020 and 16 closed out, a net change of +10 holders.
- The largest Regenxbio buyer in Q2 2020 was BlackRock, an estimated $19.1M added.
- The largest Regenxbio seller in Q2 2020 was Perceptive Advisors, an estimated $17.1M sold.
Based on aggregated 13F filings for Q2 2020.